• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Who should use hydroxychloroquine for COVID-19: Govt issues new advisory

|

New Delhi, Apr 10: An advisory on the use of hydroxychloroquine as a treatment for COVID-19 was released by the Health Ministry. The advisory is based on the recommendations of the task force constituted by the Indian Council of Medical Research (ICMR). The advisory recommend against administering the drug to children before the age of 15. It says that people with known cases of retinopathy and known hypersensitivity to hydroxychloroquine or 4-aminoquinoline compounds should not be taking the medicine.

The drug is being widely touted as the medicine which can treat COVID-19. However ICMR said it is not recommending its commercial use unless it gets satisfactory results.

Who should use hydroxychloroquine for COVID-19: Govt issues new advisory

ICMR says that hydroxychloroquine is recommended only to those asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19 and asymptomatic household contacts of laboratory confirmed cases.

India will not export hydroxychloroquine to private companies: Report

The advisory says that the most important consideration is to take the drug only after it is recommended by a registered medical practitioner. It further recommends that one must check with the physician about any adverse event before starting the medication.

The advisory also says that "if anyone becomes symptomatic while on prophylaxis, he/she should immediately contact the health facility, get tested as per national guidelines and follow the standard treatment protocol."

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more